Quick Takeaways Why It Matters? This deal gives Viromed a faster route to commercialize PulmoPlas in veterinary respiratory care, starting with horses, while NEBU-TEC gets exclusive global distribution rights in that segment. The biggest market upside is in ...
Quick Takeaways: Why It Matters? Genflow’s early canine SIRT6 data are strong enough that big animal‑health players now want a closer look, but not yet strong enough for anyone to sign a deal. The expanded web of NDAs suggests real strategic interest ...
Quick Takeaways: Why It Matters? BioTesserae’s BTC-001, a PD‑1–targeting single‑domain antibody for canine cancer, showed good tolerability in healthy dogs in a single‑ascending‑dose study, with doses up to three times the anticipated therapeutic level. Ins...
Quick Takeaways: Why It Matters? The Roslin partnership positions ProImmune’s Ankyron platform as core enabling infrastructure for veterinary immunology, filling longstanding reagent gaps that have slowed work on livestock, avian, and fish pathogens rel...
Quick Takeaways: Why It Matters? The partnership gives Gallant industrial‑grade cold-chain logistics, solving a key bottleneck for scaling allogeneic cell therapies beyond a few specialty centers. For MWI/Cencora, establishing -80°C capability positions the ...
Quick Takeaways: Why It Matters? The collaboration gives Kyoritsu access to cutting-edge microbiome and enzyme engineering capabilities, helping it move beyond traditional pharmaceuticals into differentiated biological solutions. For bitBiome, part...
